Bio-Techne ( (TECH) ) has released its Q2 earnings. Here is a breakdown of the information Bio-Techne presented to its investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Bio-Techne Corporation is a global life sciences company that provides innovative tools and bioactive reagents for research and clinical diagnostics, playing a key role in drug discovery and precision diagnostics.
In its latest earnings report for the second quarter of fiscal 2025, Bio-Techne reported a 9% increase in organic revenue, reaching $297 million. The company’s GAAP earnings per share rose to $0.22 from $0.17, while adjusted EPS increased slightly to $0.42 from $0.40 compared to the previous year.
The company’s Protein Sciences segment experienced strong performance, driven by improved conditions in the biopharma market and a boost in cell and gene therapy solutions, resulting in an 8% organic growth. Meanwhile, the Diagnostics & Spatial Biology segment saw a 12% growth, attributed to robust commercial execution.
Looking ahead, Bio-Techne remains optimistic about its growth trajectory, focusing on profitability and leveraging its diverse portfolio to empower biological discoveries and advanced therapeutics development, positioning the company for continued success in the life sciences sector.
